Back to search
FDAFDA · Food and drugs·Recall number D-0377-2015

CIPROFLOXACIN TABLETS, USP, 500 mg, 100 Tablets (10 tablets per blister card. 10 blister cards per carton), Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 51079-182-20.

Published January 28, 2015 · Recall initiated: September 26, 2013

Summary

FDA records drug Class II recall D-0377-2015, published January 28, 2015 and initiated September 26, 2013. Recalling firm: Mylan Institutional, Inc. (d.b.a. UDL Laboratories); Status: Terminated; Reported quantity: 11,650 cartons; Lot: Lot Number: 3034630; Expiration Date: 12/13; NDC: 51079-182-20. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Distributor
Nationwide and Puerto Rico.
Lot
Lot Number: 3034630; Expiration Date: 12/13; NDC: 51079-182-20
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CIPROFLOXACIN TABLETS, USP, 500 mg, 100 Tablets (10 tablets per blister card. 10 blister cards per carton), Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV --- NDC 51079-182-20. recalled?

Yes. FDA published recall D-0377-2015 on January 28, 2015. Reported hazard: CGMP Deviations: Pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices

What should I do if I have this product?

Voluntary: Firm initiated · Letter